# Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function

> **NCT02678000** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 84 (actual)

## Conditions studied

- Chronic Kidney Disease (CKD)

## Interventions

- **DRUG:** LHW090
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02678000
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-10
- **Primary completion:** 2018-10-11
- **Final completion:** 2018-10-11
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2021-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02678000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02678000, "Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02678000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*